Literature DB >> 1493084

Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation.

N G Best1, A K Trull, K K Tan, K L Hue, D J Spiegelhalter, S M Gore, J Wallwork.   

Abstract

1. The relationship between blood cyclosporin concentration (CyACb) and a patient's risk of organ rejection following heart-lung (HL) transplantation was investigated. 2. Longitudinal data were collected for 90 days post-operation for 31 HL transplant recipients. Following exploratory analysis, a multiple logistic regression model with a binary outcome variable representing presence or absence of lung rejection (as defined on biopsy findings and/or intention to treat) in the next 5 days was fitted to the data. 3. A significant interaction between time post-transplant and CyACb was found. During weeks 1-3, the relative risk (RR) of rejection per unit increase in log(e) (5-day mean CyACb) was reduced: RR = 0.29, 95% confidence interval (CI) = (0.12, 0.72). After 3 post-operative weeks, this trend was reversed: RR = 1.61, 95% CI = (0.96, 2.70). Increases in cyclosporin dose (CyAD) and in coefficient of variation (CV) for both CyAD and CyACb over the previous 10 days significantly increased the risk of rejection: RR per unit increase in log(e) (5-day mean CyAD) = 2.72, 95% CI = (1.18, 6.25); RR per increase of 10% (i.e. from, say, 20% to 30%) in the CV for CyAD = 1.20, 95% CI = (1.07, 1.36); RR if the CV for CyACb > 40% = 1.51, 95% CI = (1.01, 2.27). Administration of high dose steroids in the previous 5 days was found to protect against further rejection: RR if steroid treatment was given = 0.23, 95% CI = (0.13, 0.38).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493084      PMCID: PMC1381453          DOI: 10.1111/j.1365-2125.1992.tb05657.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Analysis of risk factors for acute allograft rejection after heart transplantation.

Authors:  M Carrier; D H Russell; R C Cork; J Wild; R W Emery; J G Copeland
Journal:  J Heart Transplant       Date:  1990 Jul-Aug

2.  Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients.

Authors:  A Trull; K Hue; K Tan; S Gore; S Whitewood; R Smyth; J Scott; C Price; J Wallwork
Journal:  Clin Chem       Date:  1990-08       Impact factor: 8.327

3.  Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.

Authors:  G Laufer; J Miholic; A Laczkovics; G Wollenek; C Holzinger; A Hajek-Rosenmeier; G Wuzl; W Schreiner; P Buxbaum; E Wolner
Journal:  J Thorac Cardiovasc Surg       Date:  1989-12       Impact factor: 5.209

4.  The impact of cyclosporine therapy on the occurrence of infection in the renal transplant recipient.

Authors:  N E Tolkoff-Rubin; R H Rubin
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

5.  Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility.

Authors:  L M Shaw; P R Audet; R A Grossman; L Fields; G L Lensmeyer; D C Dafoe
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

6.  A detailed study of cytomegalovirus infections in the first 160 heart and heart/lung transplant recipients at Papworth Hospital, Cambridge, England.

Authors:  T G Wreghitt; M Hakim; J J Gray; S Kucia; R Cory-Pearce; J Wallwork; T A English
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

7.  Heart and lung transplantation: autotransplantation and allotransplantation in primates with extended survival.

Authors:  B A Reitz; N A Burton; S W Jamieson; C P Bieber; J L Pennock; E B Stinson; N E Shumway
Journal:  J Thorac Cardiovasc Surg       Date:  1980-09       Impact factor: 5.209

Review 8.  Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy.

Authors:  B D Kahan; J Grevel
Journal:  Transplantation       Date:  1988-11       Impact factor: 4.939

9.  Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical.

Authors:  A Johansson; E Möller
Journal:  Transplantation       Date:  1990-12       Impact factor: 4.939

10.  Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.

Authors:  G C Yee; S G Self; T R McGuire; J Carlin; J E Sanders; H J Deeg
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

View more
  4 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  A nonlinear mixed-effects pharmacokinetic model comparing two formulations of cyclosporine in stable renal transplant patients.

Authors:  W M Sallas; J R Nedelman; L B Sheiner; J A Meligeni; W T Robinson
Journal:  J Pharmacokinet Biopharm       Date:  1995-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.